Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 257.46B +7.1% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.09 |
| Forward PE | 16.04 |
| Dividend | 9.80 (3.04%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 778,976 |
| Open | 322.00 |
| Previous Close | 320.70 |
| Day's Range | 317.40 - 323.50 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases,... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
Roche to set up digital technology hub in Hyderabad
Swiss Drugmaker’s Second Hub In India To Become Operational in Q1 Of 2027
Old cancer drug may help restore fertility for certain women
We also cover a large study that should allay fears of people who should be taking cholesterol-lowering statins.
Roche Secures FDA Priority Review Of Enspryng In Thyroid Eye Disease; Decision Due October 2026
(RTTNews) - Genentech, a member of Roche Holding AG (RHHBY), announced on Tuesday that it has secured the US Food and Drug Administration (FDA) priority review of its supplemental Biologics License Ap...
FDA Grants Priority Review To Genentech's Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and gra...
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scal...
Swiss pharma at risk of US trade investigation, industry body says
The United States could open a trade investigation into Switzerland's pharmaceutical industry similar to the one initiated last week against Germany, the head of Swiss industry body Interpharma said...
Louth GAA FL Round-up - Div 2: O’Raghallaighs pick up vital points as Roche open six-point lead at the top
Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination
(RTTNews) - Exelixis, Inc. (EXEL) on Monday reported final analysis results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with Roche's Tecentriq versus regorafenib in prev...
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs
The investigation comes after Berlin said it would require drugmakers to offer bigger discounts on medicines.
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether "persistent underpayment" for medicines by Germany is discriminatory. "President Trump has made clear that American patients should not be shouldering a di...
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
Quantum Strategy's David Roche expects the US-Iran deal to hold, arguing both Washington and Tehran have strong incentives to keep Iranian oil flowing and avoid political disruption ahead of US midter...
Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion
Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion
FDA Accepts Genentech's SBLA For Lunsumio-Polivy In LBCL; Decision Slated For February 2027
(RTTNews) - Genentech, a unit of Roche Holding AG (RHHBY), announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application (sBLA) for Lunsumio VELO as ...
FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Basel, June 18, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo...
FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA approves first generic version of Roche's flu drug
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wednesda...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Roche Secures FDA Approval For First PTEN IHC Companion Diagnostic In Prostate Cancer
(RTTNews) - Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from the U.S. Food and Drug A...
Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls
The proposed 10 million person limit could ruin Switzerland’s reputation as a business hub and risks harming one of Europe’s strongest economies, business leaders warn.
Roche’s global survey highlights urgent need to shift diabetes care from disease treatment to mental wellbeing
[The content of this article has been produced by our advertising partner.] Nearly one in ten people in Hong Kong now live with diabetes, and the city’s burden is growing. An ageing population, shifti...
Roche 's VENTANA MMR RxDx Panel Gains IVDR Approval Across Multiple Cancer Types
(RTTNews) - Roche (RHHBY) has secured European Union In Vitro Diagnostic Regulation (IVDR) approval for expanded use of its VENTANA MMR RxDx Panel, a companion diagnostic designed to help identify can...
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer Treatment
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer Treatment
FDA Grants Priority Review for Genentech's Tecentriq for a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MM...